Disease Landscape and Forecast Insights

Market Outlook  Squamous cell carcinoma of the head and neck ( SCCHN ) is an anatomically and biologically heterogeneous disease, which has historically proven a complex challenge for drug…

Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…

Abstract Introduction: The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar…

The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…

Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…

Non-alcoholic steatohepatitis (NASH) is a common liver disease that can progress to liver fibrosis, cardiovascular disease, and cancer. In the absence of any approved treatments for it, there is a…

Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At…

How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically receive chemotherapy…

Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…

Gastric cancer (GC) is a major public health burden in China and is the third leading cause of cancer-related deaths in the country. Although chemotherapy is the mainstay of treatment, prescribing…